Mylan N.V. late Monday posted fourth-quarter earnings that were in-line with the Wall Street consensus. The generic drug maker reported adjusted fourth-quarter earnings of $1.05 a share on revenue of $2.08 billion. Analysts surveyed by FactSet estimated $1.05 a share on revenue of $2.07 billion. Mylan forecast adjusted 2015 earnings of $4.00 to $4.30 a share on revenue of $9.6 billion to $10.1 billion. Analysts had estimated $4.05 a share on revenue of $9.09 billion. Even so, shares of Mylan declined 1.5% to $57 on moderate volume.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below